Previous 10 | Next 10 |
SERENITY III will evaluate the efficacy and safety of BXCL501 for at-home use Top-line pivotal data expected in 1H 2023 Estimated 23 million annual agitation episodes in the home-setting would more than double current market opportunity for BXCL501 in the U.S. 1 -4...
The stock market has recovered some of its losses over the past month, rising by nearly 11% in this period. Some companies are tagging along, including BioXcel Therapeutics (NASDAQ: BTAI) , a small-cap biotech stock. BioXcel remains deep in the red for the year, but ongoing developm...
Summary Currently, several pharmaceutical companies are testing candidates’ drugs and some of them are in the final stages of trials. The huge revenue potential is at stake in this race for the best anti-agitation drug for dementia and Alzheimer's patients. BioXcel's BX...
NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder a...
BioXcel Therapeutics, Inc. (BTAI) Q3 2022 Earnings Conference Call November 10, 2022 08:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial Officer Rob Ris...
BioXcel Therapeutics ( NASDAQ: BTAI ) stock rose ~17% on Thursday after the company's Q3 results which saw first ever sales of its lead drug Igalmi. The company said net revenue of $137K in Q3 resulted from early product trial with limited market access. Due to the c...
BioXcel Therapeutics press release ( NASDAQ: BTAI ): Q3 GAAP EPS of -$1.49 misses by $0.15 . Revenue of $0.14M. As of September 30, 2022, cash and cash equivalents totaled approximately $232.3 million. For further details see: BioXcel Therapeutics GAA...
IGALMI™ (dexmedetomidine) well-positioned for growth in 2023 based on increasing market access, efficient targeting, favorable market drivers, and sales force expansion in all major U.S. geographies Top-line pivotal data for TRANQUILITY II trial investigating BXCL501 for ...
BioXcel Therapeutics ( NASDAQ: BTAI ) is scheduled to announce Q3 earnings results on Thursday, November 10th, before market open. The consensus EPS Estimate is -$1.30 (-35.4% Y/Y) and the consensus Revenue Estimate is $1M Over the last 3 months, EPS estimates have see...
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its third qua...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...